Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry powder inhaler that comprises blisters and capsules. Its products include SYN006, SYN010, SYN007, Synflutide, Duasma,Synvent, and SYN011. The company was founded in 2010 and is headquartered in Taipei, Taiwan.
Frequently asked questions
What sector does Intech Biopharm Ltd (6461) operate in?
Intech Biopharm Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Intech Biopharm Ltd (6461) current stock price?
As of the latest data, Intech Biopharm Ltd stock price is NT$16.35, with a previous close of NT$15.85. Intech Biopharm Ltd gained NT$0.50 in the last trading session, representing a 3.15% increase.
What is Intech Biopharm Ltd (6461) current market capitalization?
Intech Biopharm Ltd market cap is approximately 1.80 billion.
What is Intech Biopharm Ltd (6461) Earnings Per Share (EPS)?
The trailing EPS is -NT$2.56.
Does Intech Biopharm Ltd (6461) pay dividends?
No. Intech Biopharm Ltd does not pay a dividend.
What is Intech Biopharm Ltd (6461) beta (volatility) score?
Intech Biopharm Ltd has a beta of 0.101, indicating lower volatility than the overall market.
